Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKesson
Harvard Business School
McKinsey
Mallinckrodt

Last Updated: August 11, 2022

Investigational Drug Information for Chidamide


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Chidamide?

Chidamide is an investigational drug.

There have been 120 clinical trials for Chidamide. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2019.

The most common disease conditions in clinical trials are Lymphoma, Lymphoma, T-Cell, and Lymphoma, T-Cell, Peripheral. The leading clinical trial sponsors are Sun Yat-sen University, Chinese PLA General Hospital, and Chipscreen Biosciences, Ltd.

There are three US patents protecting this investigational drug and twenty-eight international patents.

Recent Clinical Trials for Chidamide
TitleSponsorPhase
Tucidinosta Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor:a Prospective, Single-arm, Phase II Clinical Trial.wang shusenPhase 2
A Multicenter Randomized Open-label Study of Chidamide Plus HD-DEX Versus HD-DEX in ITPShandong UniversityPhase 2
Chidamide and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trialwang shusenPhase 2

See all Chidamide clinical trials

Clinical Trial Summary for Chidamide

Top disease conditions for Chidamide
Top clinical trial sponsors for Chidamide

See all Chidamide clinical trials

US Patents for Chidamide

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Chidamide See Plans and Pricing Histone deacetylase inhibitors Orchid Chemicals & Pharmaceuticals Limited (Chennai, IN) See Plans and Pricing
Chidamide See Plans and Pricing Crystal form of chidamide, preparation method and use thereof SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (Shenzhen, Guangdong, CN) See Plans and Pricing
Chidamide See Plans and Pricing Agents for killing HIV-1-infected cells and application thereof KAGOSHIMA UNIVERSITY (Kogoshima-Shi, Kagoshima, JP) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Chidamide

Drugname Country Document Number Estimated Expiration Related US Patent
Chidamide Australia AU2008309269 1989-12-31 See Plans and Pricing
Chidamide Canada CA2702536 1989-12-31 See Plans and Pricing
Chidamide European Patent Office EP2205563 1989-12-31 See Plans and Pricing
Chidamide Japan JP2011501746 1989-12-31 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKesson
Harvard Business School
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.